Previous 10 | Next 10 |
2023-10-09 19:30:05 ET Summary Merck's business has been dominated by its oncology drug Keytruda and HPV vaccine Gardasil, which have sustained its market share but are facing a reckoning in the not-too-distant future. They are slowly executing a pivot into adjacent areas of Oncol...
2023-10-05 16:53:53 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare Regeneron and Intellia expand gene editing partnership Regeneron nabs FDA priority review for lymphoma therapy For further details see:...
TARRYTOWN, N.Y., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results from the pivotal PULSAR trial investigating EYLEA ® HD (aflibercept) Injection 8 mg with 12- and 16-week d...
2023-10-05 09:15:00 ET Investing wisdom tells us to buy low, but what exactly constitutes a "low" point? Consider the case of Regeneron (NASDAQ: REGN) , a biotech company that has beaten the market in recent years. Despite its doing so, one could argue that the drugmaker, which isn'...
2023-10-03 09:06:47 ET More on MAIA Biotechnology Seeking Alpha’s Quant Rating on MAIA Biotechnology Historical earnings data for MAIA Biotechnology Financial information for MAIA Biotechnology For further details see: MAIA shares fall 17% pre-mark...
2023-10-03 07:40:17 ET More on Intellia, Regeneron, etc. Intellia Therapeutics: Massive OpEx Begin To Weigh On HAE Prospects Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 21st Annual Global He...
Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscu...
2023-09-30 05:30:00 ET Companies generally decide to engage in stock splits after their shares have soared to a level that may put them out of reach for many retail investors. A stock split doesn't change the real market value of a company, nor does it alter the value of any investor's hold...
2023-09-29 10:57:42 ET More on Regeneron Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Management P...
If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two most common subtypes of non-Hodgkin lymphoma European Medicines Agency also reviewing odronextamab Marketing Authorization Application TARRYTOWN, N.Y., Se...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...